 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 7/11/2006
| Lisa A. Carey, M.D.
Associate Professor |  |
Clinical Interests
Dr. Carey is board-certified in both Internal Medicine and Medical Oncology. Her clinical interest is in breast cancer, and she is the Medical Director of the UNC Breast Center.
Research Interests
Dr. Carey's research interests also focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early breast cancer, and examination of tumor characteristics that predict response to therapy.
The members of the UNC Breast Center have a long commitment to improving treatment of early (nonmetastatic) breast cancer, and have been early investigators in the use of neoadjuvant, or preoperative, chemotherapy for breast cancer. In part based upon work performed at UNC, we now know that women do just as well if their chemotherapy is given before surgery as after, however the chemotherapy-first approach means that they are more likely to save their breast. In addition, with neoadjuvant therapy it is possible to tell if the drugs are working since the tumor is still measurable when the chemotherapy is given first. Dr. Carey's clinical research program investigates new drugs and combination of drugs in neoadjuvant therapy. As part of her neoadjuvant chemotherapy program, she is also involved in several studies, including a multiinstitutional trial sponsored by the National Cancer Institute, of genetic and molecular markers in breast cancer as predictors of response to chemotherapy. Dr. Carey is also the principal investigator of a highly collaborative study examining genes that might interact with other genes or with the environment to impact on a woman's risk of developing breast cancer.
For her work, she was awarded a Doris Duke Clinical Scientist Award in 1999 and a career development award from the National Cancer Institute in 2000.
Training
M.D., Johns Hopkins School of Medicine 1990
Resident, Internal Medicine, Johns Hopkins 1990-3
Fellow, Medical Oncology, Johns Hopkins 1993-8
Sc.M., Clinical Investigations, Johns Hopkins School of Public Health 1994-8
Publications
Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, Cush S, Carey LA. Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine-Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control. Clinical Cancer Research, in press.
Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood Vessel Morphological Changes as Visualized by MRA During Treatment of Brain Metastases. Radiology, in press.
Carey LA, Dees EC, Sawyer LR, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research 13:2329-2334, 2007.
Lillie SE, Brewer NT, ONeill SC, Morrill EF, Dees EC, Carey LA, Rimer BK. Retention and use of breast cancer recurrence risk information from genomic tests: The role of health literacy. Cancer Epidemiology Biomarkers and Prevention 16(2):249-55, 2007.
Bullitt E, Lin N, Ewend M, Zeng D, Winer E, Carey L, Smith JK. Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer. Medical image computing and computer-assisted intervention 4191:561-568, 2006.
Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Clinical and pathologic response rate and cardiotoxicity of neoadjuvant trastuzumab given in conjunction with weekly paclitaxel after AC. Clin Breast Cancer; 7(3):237-243, 2006
-----------------------------------------------------
Bullitt E, Lin NU, Ewend MG, Zeng D, Winer EP, Carey LA, Smith JK. Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer. Lecture Notes in Computer Science, in press.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA; 295(21):2492-502, (2006).
Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24 (11):1656-1664 (2006).
Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N. Axillary Lymph Node Count is Lower after Neoadjuvant Chemotherapy. American Journal of Surgery; 191(6):827-9, (2006).
Klauber-Demore N, Ollila DW, Moore DT, Livasy C, Calvo BF, Kim HJ, Dees EC, Sartor CI, Sawyer LR, Graham M, Carey LA. Size of Residual Lymph Node Metastases Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients is Prognostic. Ann Surg Onc; 13(5):685-91 (2006).
Hu Z, Fan C, Oh D, Marron JS, He X, Qaquish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend M, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Orrico AR, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The Molecular Portraits of Breast Tumors Are Conserved Across Microarray Platforms. BMC Genomics 7:96, (2006).
Kaufmann WK, Filatov L, Oglesbee SE, Simpson DA, Lotano MA, McKeen HD, Sawyer LR, Moore DT, Millikan RC, Cordeiro-Stone M, Carey LA. Radiation clastogenesis and cell cycle checkpoint function as markers of ataxia telangiectasia and breast cancer. Carcinogenesis;June 15, (2006).
Ewend MG, Elbabaa S, Carey LA. Current treatment paradigms for the management of patients with brain metastases (review). Neurosurgery 57(5):S4-66-4-77 (2005)
Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, vant Veer LJ. Molecular Portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Research 65(20):9155-9158 (2005).
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer- ready for clinical application? J Clin Oncol 23(29):7350-60 (2005).
Carey LA, Tripathy D, Dowsett M, Winer E. Beyond Anatomic Staging...Is it Time to Take the Leap into Molecular Classification? Proc Am Soc Clin Oncol Educational Book: 46-59 (2005)
Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-Demore N, Halle J, Sawyer L, Amamo A, Moore DT, Graham ML. Residual tumor assessed by the revised American Joint Commission on Cancer (AJCC) staging system provides a simple prognostic index for breast cancer after neoadjuvant chemotherapy. J National Cancer Institute 97:1137-1142, 2005.
Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-Demore N. Lymphatic Mapping and Sentinel Lymphadenectomy Prior to Neoadjuvant Chemotherapy in Patients with Large Breast Cancers. American Journal of Surgery 190(3):371-375, 2005.
Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, Moore DT, Graham MG. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Research and Treatment 88 (3):273-280, 2004.
Carey LA. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer (review). Breast Diseases: A Year Book Quarterly 14 (4):435, 2004.
Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M, Collins EJ, Frelinger JA, Van Deventer H, Collichio F, Carey LA, Brecher M, Graham M, Earp HS, Serody JS. Dendritic cells can be rapidly expanded ex vivo and administered safely in patients with metastatic breast cancer. Cancer Immunology and Immunotherapy 53(9):777-85, 2004.
Klauber-DeMore N, Kuzmiak C, Rager EL, Ogunride OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees EC, Graham M, Collichio FA, Sartor CI, Metzger R, Carey LA. High resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. American Journal of Surgery 188(4):386-369, 2004.
Cance WG and Carey LA* , Calvo B, Sawyer L, Rosenman J, Graham ML (*co-first author). Long-term Outcome of Neoadjuvant Therapy for Advanced Breast Carcinoma: Effective Clinical Downstaging Allows Breast Preservation and Predicts Outstanding Local Control and Survival. Annals Surgery 336(3):295-303, 2002.
Ollila DW, Carey LA, Sartor CI. Clinical significance of micrometastatic disease in the era of the sentinel node. Breast Disease 12;57-67, 2001.
Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Brain metastases. Current Treatment Options in Oncology 2;537-547, 2001.
E-mail: Lisa_Carey@med.unc.edu
Telephone: (919) 966-4431
FAX: (919) 966-6735
Address: 3009 Old Clinic Bldg. Chapel Hill, NC 27599-7305
